GlobalRPh RX List - Vanrafia
- Product / population
- VANRAFIA oral product; selected renal pharmacokinetic evidence, not a complete treatment-eligibility assessment.
- Renal measure
- CKD-EPI indexed eGFR, mL/min/1.73 m2.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
No clinically meaningful pharmacokinetic difference was identified across the studied eGFR range 15-90. The effect of end-stage renal disease below 15 is unknown. These are pharmacokinetic observations; they do not establish a dialysis regimen or override the product's indication, monitoring and safety criteria. No numerical dose adjustment is inferred from the exposure findings.